Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Vicore Pharma Holding ABNASDAQ: VCRE

Other Working Capital · Q2 FY2026 · quarter ended Jun 2026

Other working capital outflow shrinks to SEK 0

Q2 FY2026 other working capital was SEK 0, compared with SEK 4.06M a year earlier. Trailing-twelve-month other working capital was SEK 48.33M.

Context

  • Other working capital amounted to 1149.9% of revenue in FY2025, up 1119.0 pp from a year earlier.
  • Other working capital increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other working capital holds near SEK 0 or moves back toward the trailing-twelve-month quarterly average of SEK 12.08M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 0+100.0% QoQ
Last fiscal yearDec 2025
SEK 43.89M+30.0% YoY
LTMJun 2026
SEK 48.33M+89.2% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+30.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

SEK · from the cash flow

Latest · FY2025
43.89M SEK
Year-over-year change
+30.0%

Other Working Capital vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +89.2% is the lowest of 2, against a peer median of +1489.4%.
  • Other working capital amounts to 3634.1% of revenue for VCRE, versus a peer median of 32.0%.
VCRE Competitors
Other Working Capital for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$144.23M USD+1489.4%—32.0%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 48.33M SEK+89.2%—3634.1%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+1489.4%—32.0%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.